Veralipride
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Veralipride
- DrugBank Accession Number
- DB13523
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 383.46
Monoisotopic: 383.151492091 - Chemical Formula
- C17H25N3O5S
- Synonyms
- Veraliprida
- Veralipride
- Veralipridum
- External IDs
- LIR 1660
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Veralipride. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Veralipride. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Veralipride. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Veralipride. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Veralipride. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Agradil / Agreal
Categories
- ATC Codes
- N05AL06 — Veralipride
- Drug Categories
- Acids, Carbocyclic
- Amides
- Antipsychotic Agents
- Benzamides and benzamide derivatives
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Central Nervous System Depressants
- Menopause, drug effects
- Nervous System
- Neurotoxic agents
- Psycholeptics
- Psychophysiologic Disorders, drug therapy
- Psychotropic Drugs
- Tranquilizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzenesulfonamides. These are organic compounds containing a sulfonamide group that is S-linked to a benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzenesulfonamides
- Direct Parent
- Benzenesulfonamides
- Alternative Parents
- Dimethoxybenzenes / Benzenesulfonyl compounds / Benzamides / Phenoxy compounds / Benzoyl derivatives / Anisoles / Alkyl aryl ethers / Organosulfonamides / N-alkylpyrrolidines / Aminosulfonyl compounds show 7 more
- Substituents
- Alkyl aryl ether / Amine / Amino acid or derivatives / Aminosulfonyl compound / Anisole / Aromatic heteromonocyclic compound / Azacycle / Benzamide / Benzenesulfonamide / Benzenesulfonyl group show 28 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S7064109UD
- CAS number
- 66644-81-3
- InChI Key
- RYJXBGGBZJGVQF-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H25N3O5S/c1-4-7-20-8-5-6-12(20)11-19-17(21)14-9-13(26(18,22)23)10-15(24-2)16(14)25-3/h4,9-10,12H,1,5-8,11H2,2-3H3,(H,19,21)(H2,18,22,23)
- IUPAC Name
- 2,3-dimethoxy-N-{[1-(prop-2-en-1-yl)pyrrolidin-2-yl]methyl}-5-sulfamoylbenzamide
- SMILES
- COC1=CC(=CC(C(=O)NCC2CCCN2CC=C)=C1OC)S(N)(=O)=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 43638
- 39468
- ChEBI
- 135600
- ChEMBL
- CHEMBL2105581
- Wikipedia
- Veralipride
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule, coated Oral 100 mg Capsule - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.285 mg/mL ALOGPS logP 1.52 ALOGPS logP 0.55 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 10.06 Chemaxon pKa (Strongest Basic) 7.77 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 110.96 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 99.51 m3·mol-1 Chemaxon Polarizability 39.87 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-1009000000-46d66e3d2a073ee6d387 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-001l-0009000000-91745c1ece090ae0729c Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-2209000000-b10ff7ffff38ac40f3a4 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-01t9-4109000000-65e59c84ed443536c96b Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-000w-9242000000-8b74e20fc0a27b51620c Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9024000000-acd1e62d17eb03268b28 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 183.77238 predictedDeepCCS 1.0 (2019) [M+H]+ 186.13039 predictedDeepCCS 1.0 (2019) [M+Na]+ 192.22354 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:43 / Updated at February 21, 2021 18:54